CXCL9 and neoplasm: Indeed, the link between CXCR3 ligands, including both CXCL9 and CXCL10 in promoting anti-tumour immunity is becoming increasingly recognised, with their expression correlating with improved patient responses and sensitisation to immune checkpoint blockade in pan-cancer studies (60, 100, 101).